1
|
Nakagama S, Maejima Y, Fan Q, Shiheido-Watanabe Y, Tamura N, Ihara K, Sasano T. Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity. JACC CardioOncol 2023; 5:656-670. [PMID: 37969644 PMCID: PMC10635891 DOI: 10.1016/j.jaccao.2023.05.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 05/09/2023] [Accepted: 05/15/2023] [Indexed: 11/17/2023] Open
Abstract
Background The administration of anthracycline drugs induces progressive and dose-related cardiac damage through several cytotoxic mechanisms, including endoplasmic reticulum (ER) stress. The unfolded protein response plays a crucial role for mitigating misfolded protein accumulation induced by excessive ER stress. Objectives We aimed to clarify whether endoplasmic reticulum-selective autophagy machinery (ER-phagy) serves as an alternative system to protect cardiomyocytes from ER stress caused by anthracycline drugs. Methods Primary cultured cardiomyocytes, H9c2 cell lines, and cardiomyocyte-specific transgenic mice, all expressing ss-RFP-GFP-KDEL proteins, were used as ER-phagy reporter models. We generated loss-of-function models using RNA interference or gene-trap mutagenesis techniques. We assessed phenotypes and molecular signaling pathways using immunoblotting, quantitative polymerase chain reaction, cell viability assays, immunocytochemical and histopathological analyses, and cardiac ultrasonography. Results The administration of doxorubicin (Dox) activated ER-phagy in ss-RFP-GFP-KDEL-transduced cardiomyocytes. In addition, Dox-induced cardiomyopathy models of ER-phagy reporter mice showed marked activation of ER-phagy in the myocardium compared to those of saline-treated mice. Quantitative polymerase chain reaction analyses revealed that Dox enhanced the expression of cell-cycle progression gene 1 (CCPG1), one of the ER-phagy receptors, in H9c2 cells. Ablation of CCPG1 in H9c2 cells resulted in the reduced ER-phagy activity, accumulation of proapoptotic proteins, and deterioration of cell survival against Dox administration. CCPG1-hypomorphic mice developed more severe deterioration in systolic function in response to Dox compared to wild-type mice. Conclusions Our findings highlight a compensatory role of CCPG1-driven ER-phagy in reducing Dox toxicity. With further study, ER-phagy may be a potential therapeutic target to mitigate Dox-induced cardiomyopathy.
Collapse
Affiliation(s)
- Shun Nakagama
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Qintao Fan
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yuka Shiheido-Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Natsuko Tamura
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Kensuke Ihara
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
- Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
| | - Tetsuo Sasano
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
2
|
Shiheido-Watanabe Y, Maejima Y, Nakagama S, Fan Q, Tamura N, Sasano T. Porphyromonas gingivalis, a periodontal pathogen, impairs post-infarcted myocardium by inhibiting autophagosome-lysosome fusion. Int J Oral Sci 2023; 15:42. [PMID: 37723152 PMCID: PMC10507114 DOI: 10.1038/s41368-023-00251-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/04/2023] [Accepted: 09/04/2023] [Indexed: 09/20/2023] Open
Abstract
While several previous studies have indicated the link between periodontal disease (PD) and myocardial infarction (MI), the underlying mechanisms remain unclear. Autophagy, a cellular quality control process that is activated in several diseases, including heart failure, can be suppressed by Porphyromonas gingivalis (P.g.). However, it is uncertain whether autophagy impairment by periodontal pathogens stimulates the development of cardiac dysfunction after MI. Thus, this study aimed to investigate the relationship between PD and the development of MI while focusing on the role of autophagy. Neonatal rat cardiomyocytes (NRCMs) and MI model mice were inoculated with wild-type P.g. or gingipain-deficient P.g. to assess the effect of autophagy inhibition by P.g. Wild-type P.g.-inoculated NRCMs had lower cell viability than those inoculated with gingipain-deficient P.g. This study also revealed that gingipains can cleave vesicle-associated membrane protein 8 (VAMP8), a protein involved in lysosomal sensitive factor attachment protein receptors (SNAREs), at the 47th lysine residue, thereby inhibiting autophagy. Wild-type P.g.-inoculated MI model mice were more susceptible to cardiac rupture, with lower survival rates and autophagy activity than gingipain-deficient P.g.-inoculated MI model mice. After inoculating genetically modified MI model mice (VAMP8-K47A) with wild-type P.g., they exhibited significantly increased autophagy activation compared with the MI model mice inoculated with wild-type P.g., which suppressed cardiac rupture and enhanced overall survival rates. These findings suggest that gingipains, which are virulence factors of P.g., impair the infarcted myocardium by cleaving VAMP8 and disrupting autophagy. This study confirms the strong association between PD and MI and provides new insights into the potential role of autophagy in this relationship.
Collapse
Affiliation(s)
- Yuka Shiheido-Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
| | - Shun Nakagama
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Qintao Fan
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Natsuko Tamura
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Tetsuo Sasano
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
3
|
Ohira M, Kobayashi T, Tanaka Y, Imaoka Y, Sato K, Imaoka K, Nakano R, Doskali M, Piao J, Nakamura M, Yoshida T, Ichinohe T, Kawano R, Yoshimura K, Ueda K, Tamura N, Hirata T, Imamura M, Aikata H, Tanimine N, Kuroda S, Tahara H, Ide K, Ohdan H. Adoptive immunotherapy with natural killer cells from peripheral blood CD34 + stem cells to prevent hepatocellular carcinoma recurrence after curative hepatectomy: a study protocol for an open-label, single-arm phase I study. BMJ Open 2022; 12:e064526. [PMID: 36410831 PMCID: PMC9680173 DOI: 10.1136/bmjopen-2022-064526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Hepatocellular carcinoma (HCC) remains a major clinical problem as more than half of these cases recur after radical resection. Natural killer (NK) cells are at the forefront of the innate immune system and attack microcarcinomas and circulating tumour cells. The objective of this study was to evaluate the feasibility and toxicity of peripheral blood CD34+ stem cell-derived NK cell infusion after radical hepatectomy for HCC. METHODS AND ANALYSIS This is an open-label, single-arm, single-centre phase I study. Patients who have undergone initial hepatectomy for HCC with three or more risk factors for recurrence (≥10 ng/mL of Alpha fetoprotein (AFP), ≥360 mAU/mL of PIVKA-II, multiple tumours and ≥3 peripheral blood circulating tumour cells) will be enrolled and be treated with three peripheral blood CD34+ stem cell-derived NK cell infusions every 3 months. The primary endpoint will be safety assessment including the type and severity of adverse events, frequency of occurrence and duration of occurrence. The secondary endpoints will include survival, effect of immune response and clinical laboratory test results. ETHICS AND DISSEMINATION Ethical approval of the trial was obtained from the Certified Committee for Regenerative Medicine Hiroshima University in Japan. The trial results will be shared with the scientific community at international conferences and by publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER jRCTb060200020.
Collapse
Affiliation(s)
- Masahiro Ohira
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
- Medical Center for Translational and Clinical Research, Hiroshima University, Hiroshima, Japan
| | - Tsuyoshi Kobayashi
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Yuka Tanaka
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Yuki Imaoka
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Koki Sato
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Koki Imaoka
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Ryosuke Nakano
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Marlen Doskali
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Jinlian Piao
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Mayuna Nakamura
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Tetsumi Yoshida
- Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan
| | - Tatsuo Ichinohe
- Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan
| | - Reo Kawano
- Clinical Research Center, Hiroshima University Hospital, Hiroshima, Japan
| | - Kenichi Yoshimura
- Medical Center for Translational and Clinical Research, Hiroshima University, Hiroshima, Japan
| | - Keiko Ueda
- Clinical Research Center, Hiroshima University Hospital, Hiroshima, Japan
| | - Natsuko Tamura
- Clinical Research Center, Hiroshima University Hospital, Hiroshima, Japan
| | - Taizo Hirata
- Clinical Research Center, Hiroshima University Hospital, Hiroshima, Japan
| | - Michio Imamura
- Department of Gastroenterology, Hiroshima University, Hiroshima, Japan
| | - Hiroshi Aikata
- Department of Gastroenterology, Hiroshima University, Hiroshima, Japan
| | - Naoki Tanimine
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Shintaro Kuroda
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Hiroyuki Tahara
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Kentaro Ide
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
| | - Hideki Ohdan
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
- Clinical Research Center, Hiroshima University Hospital, Hiroshima, Japan
| |
Collapse
|
4
|
Sano M, Maejima Y, Nakagama S, Shiheido-Watanabe Y, Tamura N, Hirao K, Isobe M, Sasano T. Neutrophil extracellular traps-mediated Beclin-1 suppression aggravates atherosclerosis by inhibiting macrophage autophagy. Front Cell Dev Biol 2022; 10:876147. [PMID: 35923856 PMCID: PMC9340257 DOI: 10.3389/fcell.2022.876147] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 06/30/2022] [Indexed: 11/13/2022] Open
Abstract
A growing body of evidence suggests that neutrophil extracellular traps (NETs) critically contribute to the development of atherosclerosis. However, the detailed mechanism of how NETs promote atherogenesis remains unknown. In this study, we explored the role of NETs for promoting atherosclerosis by modulating the activity of autophagy in macrophages. NETs were effectively induced by a nicotine administration to the HL-60 cell-derived neutrophil-like cells. Treatment with NETs markedly suppressed both autophagosome formation and autophagosome–lysosome fusion in 7-ketocholesterol-treated macrophages, which are accompanied by the enhancement of inflammasome activity. NETs upregulate epidermal growth factor receptor (EGFR) activity, which enhances Beclin-1 phosphorylation of the tyrosine residues of Beclin-1 by EGFR, inhibits the PI3 kinase activity of the Beclin1–Vps34 complex, and suppresses autophagosome formation in macrophages. Furthermore, NET-induced activation of EGFR allows Rubicon to increase its expression, thereby suppressing autophagosome-lysosome fusion. In vivo experiments revealed that the suppression of NET formation by ablating peptidyl arginine deiminase-4 in neutrophil leukocytes resulted in the attenuation of atherosclerotic plaques in a nicotine-administered HFD-fed ApoE−/−mice. Taken together, these results suggest that NET-mediated EGFR–Beclin-1 signaling in the macrophages promotes atherogenesis by autophagy inhibition-mediated inflammasome activation.
Collapse
Affiliation(s)
- Masataka Sano
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
- Department of Professional Development, Tokyo Medical and Dental University Hospital, Tokyo, Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
- *Correspondence: Yasuhiro Maejima,
| | - Shun Nakagama
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Yuka Shiheido-Watanabe
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Natsuko Tamura
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Kenzo Hirao
- Department of Cardiovascular Medicine, AOI Universal Hospital, Kawasaki, Japan
| | | | - Tetsuo Sasano
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| |
Collapse
|
5
|
Miyamae T, Manabe Y, Sugihara T, Umezawa N, Yoshifuji H, Tamura N, Abe Y, Furuta S, Kato M, Kumagai T, Nakamura K, Nagafuchi H, Ishizaki J, Nakano N, Atsumi T, Karino K, Amano K, Kurasawa T, Ito S, Yoshimi R, Ogawa N, Banno S, Naniwa T, Ito S, Hara A, Hirahara S, Uchida HA, Onishi Y, Murakawa Y, Komagata Y, Nakaoka Y, Harigai M. POS0794 PREGNANCY AND CHILDBIRTH IN TAKAYASU ARTERITIS IN JAPAN – A NATIONWIDE RETROSPECTIVE STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundTakayasu arteritis (TAK), a granulomatous large vessel vasculitis, mainly involves the aorta and its proximal branches and commonly occurs in young females. However, studies of pregnancy in women with TAK are sparse and limited, probably due to the rarity of the disease.ObjectivesThe purpose of this study was to understand the status quo of medical treatments of the primary disease and outcomes of pregnancy in patients with TAK, and birth outcomes of the children in Japan.MethodsPatients with TAK who conceived after the onset of the disease and were managed at medical facilities participating in the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) were retrospectively enrolled in this study. The following information was collected from patients who had a live-born baby: age at diagnosis of TAK, disease classification, age at delivery, treatments before and during pregnancy, complications during pregnancy, birth outcomes of the children, and changes in disease activity during pregnancy and after delivery.ResultsFifty-one cases and 69 pregnancies from 19 ethics committee-approved centers were enrolled during the study period 2019–2021. Of these, 49 cases and 66 pregnancies (95.7%) resulted in delivery and live-born babies. The Numano classification of the 49 cases was as follows: type I, 11; type IIa, 15; type IIb,12; type III, 1; type IV, 1; type V, 9; with type IIa being the most common. The age of diagnosis was 22 years (13–37 years, year of diagnosis 1965–2017), the median age of the delivery of 66 pregnancies was 31 years (year of delivery 1969-2021), and the median duration of illness at delivery was nine years. There were 34 planned pregnancies (51.5%, including four pregnancies by artificial insemination/ovulation induction). Preconception therapy included prednisolone (PSL) in 51 pregnancies (77.3%, median dose 7.5 mg (range 4–30 mg)/day), immunosuppressive drugs in 18 pregnancies (27.3%, azathioprine 8, tacrolimus 7, methotrexate 4, cyclosporin A 1, and colchicine 1), biologics in 12 pregnancies (18.1%, infliximab 6, tocilizumab 5, and adalimumab 1), antihypertensive drugs in 5 pregnancies (7.6%). Surgical treatment had been performed before pregnancy in 6 cases (aortic root replacement 2, subclavian artery dilatation 1, subclavian artery bypass 1, subclavian artery stenting 1, and ascending aorta semicircular artery replacement 1). Medications used during the course of pregnancy included PSL in 48 pregnancies (72.7%, median dose 8 mg (range 4–30 mg)/day, increased in 13 pregnancies, decreased in 1 pregnancy), immunosuppressants in 13 pregnancies (19.7%, azathioprine 6, tacrolimus 6, and cyclosporin A 1), biologics 9 pregnancies (13.6%, infliximab 4, tocilizumab 4, and adalimumab 1). Immunosuppressants and biologics were discontinued in five and four pregnancies after conception. Complications during pregnancy were observed in 20 pregnancies (30.3%), with hypertension being the most common. Complications related to TAK or its treatment were severe infections in two pregnancies and aneurysm enlargement due to increased circulating plasma volume in one pregnancy. Aortic arch replacement was performed after delivery for the latter case. Relapse of TAK was observed in 4 pregnancies (6.1%) during pregnancy and in 8 pregnancies (12.1%) after delivery. One pregnancy resulted in restenosis of subclavian artery for which dilatation procedure was performed prior to the pregnancy. There were 13/66 (19.7%) preterm infants and 17/59 (28.8%) low birth weight infants; all but one had a birth weight of more than 2,000 g and no had serious postnatal abnormalities. Forty-three (82.7%) of the 52 confirmed infants were breastfeed fully or mixed.ConclusionMost of the pregnancies in patients with TAK were successfully delivered while they had low disease activity at a dose of less than 10 mg/day of PSL. Relapse occurred during pregnancy and after delivery in some cases. The babies tended to have low birth weight, but 82.7% of them were breastfed without serious complications.Disclosure of InterestsTakako Miyamae: None declared, Yusuke Manabe: None declared, takahiko sugihara Speakers bureau: TS has received honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co., Grant/research support from: TS has received research grants from AsahiKASEI Co., Ltd., Daiichi Sankyo., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical., Natsuka Umezawa: None declared, Hajime Yoshifuji Speakers bureau: HY has received lecture fees from Janssen and Chugai., Naoto Tamura: None declared, Yoshiyuki Abe: None declared, Shunsuke Furuta Speakers bureau: Chugai Pharmaceutical Co.,Ltd.DaiichiSankyo Co.,Ltd.Asahi-Kasei Pharma Corporation, Manami Kato: None declared, Takashi Kumagai: None declared, Kaito Nakamura: None declared, Hiroko Nagafuchi: None declared, Jun Ishizaki: None declared, Naoko Nakano: None declared, Tatsuya Atsumi Speakers bureau: Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie Inc., Eisai Co. Ltd., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb Co., UCB Japan Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd.,TAIHO PHARMACEUTICAL CO., LTD., Consultant of: AstraZeneca plc., MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., Pfizer Inc., AbbVie Inc., ONO PHARMACEUTICAL CO. LTD.,Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., Grant/research support from: Astellas Pharma Inc., TAIHO PHARMACEUTICAL CO., LTD.AbbVie Inc., Nippon Boehringer Ingelheim Co., Ltd.,Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd. and Pfizer Inc. Alexion Inc., TEIJIN PHARMA LIMITED., Kohei Karino: None declared, Koichi Amano Speakers bureau: AbbVie GK, Asahi-Kasei Pharma, Astellas, Chugai Pharmaceutical Co.Ltd., Eisai, Eli Lilly, GlaxoSmithKlein, Janssen Pharma, Pfizer Japan, Grant/research support from: Asahi-Kasei Pharma,Chugai Pharmaceutical Co.Ltd., Takahiko Kurasawa: None declared, Shuichi Ito: None declared, Ryusuke Yoshimi: None declared, Noriyoshi Ogawa: None declared, Shogo Banno: None declared, Taio Naniwa Speakers bureau: Chugai, Tanabe, Abbbvie, Eisai, Grant/research support from: Chugai, Tanabe, Abbbvie, Eisai, Satoshi Ito Speakers bureau: SI has received speaker’s fees from pharmaceutical companies., Akinori Hara: None declared, Shinya Hirahara: None declared, Haruhito A. Uchida: None declared, Yasuhiro Onishi: None declared, Yohko Murakawa Speakers bureau: Astellas, UCB, Chugai, AbbVie, Grant/research support from: Chugai, AbbVie, Yoshinori Komagata: None declared, Yoshikazu Nakaoka: None declared, Masayoshi Harigai Speakers bureau: MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Novartis Japan, Pfizer Japan Inc., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd and UCB Japan., Consultant of: MH is a consultant for AbbVie, Boehringer-Ingelheim, Kissei Pharmaceutical Co., Ltd., and Teijin Pharma.
Collapse
|
6
|
Kawamoto T, Amano H, Matsushita S, Minowa K, Matsushita M, Yamaji K, Amano A, Tamura N. OP0238 CLINICAL ANALYSIS OF 34 CASES OF CARDIAC COMPLICATIONS REQUIRING SURGICAL INTERVENTION IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ASSESSMENT ABOUT MECHANISM OF DEVELOPMENT WITH IMMUNOLOGICAL ANALYSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIn cases of systematic lupus erythematosus (SLE) that lead to surgery due to the development of heart diseases such as valvular disease, ischemic heart disease and aortic aneurysm, early detection and careful monitoring are important. An absence of background diseases or immunopathological examination of the myocardial tissue in SLE cases with cardiovascular lesions demonstrates the lack of knowledge in this area. In recent years, however, there have been reports of neutrophil extracellular traps being involved in the fulminant onset of SLE.ObjectivesThis study aimed to analyze clinically and immunohistopathologically the pathophysiology of heart diseases associated with SLE.MethodsWe performed left atrial appendage resection in 34 patients, including patients with cardiovascular lesions, who underwent heart surgery for SLE complications from 2012 to 2021. Tissue analysis was conducted in 9 cases. The left atrial appendage, in cases of non-collagen valvular disease, was used as the control. Tissue staining of cardiomyocytes was carried out by adding anti-neutrophil extracellular(NE) antibodies(Abs) to anti-human IgG antibody (Ab), anti-IgM Ab and anti-C3 Ab.ResultsOf the 34 SLE patients 14 had valvular disease, 8 had ischemic heart disease and 12 had aneurysms. Preoperative SLE activity was relatively stable with only 1 patient below the CH50 standard and 6 patients above the anti-DNA Ab standard. The Ab positivity rate for the patients in this study was higher than that of the 687 SLE patients who were previously tested in 2019. The presence of anti-CL Abs was 55.6%, which was higher than the 25.5% observed in previous SLE patients. In this study, anti-SS-A and anti-RNP Abs tended to be relatively numerous. An example of immunohistochemical staining of IgG in the left atrial appendage is presented (Figure 1a). IgG deposits were not observed on the left side of the myocardial fibers in the control group, whereas IgG deposits were observed on the right side in the SLE group. Deposits were also observed in tissues that were not located in the affected areas. The presence or absence of tissue deposition in the myocardial fibers and clinical findings in 2 cases of the control group and 9 cases of the SLE complication group are reported in Table 1. IgG deposits were found in the myocardial fibers of 6 of the 9 patients in the SLE complication group, and deposits were found in the left atrial appendage tissue regardless of the type of heart disease, suggesting a potential change in the heart tissue. In the SLE group, 5 cases were positive for antiphospholipid (APS) Abs, while 7 cases were positive for either anti-SS-A or anti-RNP Abs. Only 2 cases had elevated preoperative anti-DNA Ab and complement reduction. Of the SLE complication group, 2 of the 9 cases were negative for all Abs but IgG deposits were observed in a case. Of these 4 cases were selected and stained with anti-IgM, anti-C3 and anti-NE Abs. However IgM and C3 deposits were only observed in one patient who developed myocardial infarction at the age of 39 and was triple positive for APS, anti-SS-A and anti-RNP Abs (Figure 1b). There were also no NE deposits in any of the cases. Even if complement and anti-DNA Ab levels in the serum are normal, attention should be paid to heart disease complications during the long-term observation of SLE patients. In particular, attention should be paid to various autoantibody-positive cases such as APS, anti-SS-A Ab and anti-RNP Ab. The anti-NE Ab was not stained in this study because the tissue was different from the lesion site and because it occurred during the chronic course.ConclusionIn SLE patients who developed cardiovascular lesions and required surgery, immunological abnormalities may occur in the myocardial tissue even if serum complement and anti-DNA Ab levels are stable.References[1]Stephane Zuily et al. Valvular Curr Rheumatol Rep (2013) 15:320.[2]Zawadowski GM et al. Lupus. 2012;21(13):1378-84.[3]Daniel Appelgren et al. Autoimmunity 2018,vol51,No.6,310-318.Disclosure of InterestsNone declared
Collapse
|
7
|
Yamasaki K, Yanagi O, Sunada Y, Hatta K, Shigesada R, Sumino M, Yamaguchi T, Islam MA, Tamura N, Okuno H, Namba S. Discharge characteristics of steady-state high-density plasma source based on cascade arc discharge with hollow cathode. Rev Sci Instrum 2022; 93:053502. [PMID: 35649751 DOI: 10.1063/5.0076388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Accepted: 04/18/2022] [Indexed: 06/15/2023]
Abstract
We developed a steady-state high-density plasma source by applying a hollow cathode to a cascade arc discharge device. The hollow cathode is made of a thermionic material (LaB6) to facilitate plasma production inside it. The cascade arc discharge device with the hollow cathode produced a stationary plasma with an electron density of about 1016 cm-3. It was found that the plasma source produces a strong pressure gradient between the gas feed and the vacuum chamber. The plasma source separated the atmospheric pressure (100 kPa) and a vacuum (100 Pa) when the discharge was performed with an argon gas flow rate of 5.0 l/min and a discharge current of 40 A. An analysis of the pressure gradient along the plasma source showed that the pressure difference between the gas feed and the vacuum chamber can be well described by the Hagen-Poiseuille flow equation, indicating that the viscosity of the neutral gas is the dominant factor for producing this pressure gradient. A potential profile analysis suggested that the plasma was mainly heated within cylindrical channels whose inner diameter was 3 mm. This feature and the results of the pressure ratio analysis indicated that the temperature, and, thus, viscosity, of the neutral gas increased with the increasing number of intermediate electrodes. The discharge characteristics and shape of the hollow cathode are suitable for plasma window applications.
Collapse
Affiliation(s)
- K Yamasaki
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - O Yanagi
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - Y Sunada
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - K Hatta
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - R Shigesada
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - M Sumino
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - T Yamaguchi
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - Md Anwarul Islam
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - N Tamura
- Deptartment of Helical Plasma Research, National Institute for Fusion Science, 322-6 Oroshi-cyo, Toki, Gifu 509-5292, Japan
| | - H Okuno
- Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama 351-0198, Japan
| | - S Namba
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-hiroshima, Hiroshima 739-8527, Japan
| |
Collapse
|
8
|
Ito Y, Maejima Y, Nakagama S, Shiheido-Watanabe Y, Tamura N, Sasano T. Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa-PAR2-Mediated Autophagy Suppression. JACC Basic Transl Sci 2021; 6:964-980. [PMID: 35024502 PMCID: PMC8733676 DOI: 10.1016/j.jacbts.2021.09.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 09/30/2021] [Accepted: 09/30/2021] [Indexed: 12/17/2022]
Abstract
The authors showed a mechanism for attenuating atherosclerosis by directly administering an oral factor Xa inhibitor (ie, rivaroxaban [RIV]). The autophagy activity of macrophages was significantly suppressed by factor Xa and was alleviated by the administration of RIV. However, factor Xa failed to inhibit 7-ketocholesterol-induced autophagy and inflammasome activation in protease-activated receptor 2 (PAR2) knockout macrophages. The atherosclerotic area of apolipoprotein E knockout mice was significantly reduced by the genetic ablation of PAR2, which was partially reversed by chloroquine. Thus, the authors found that RIV attenuates atherogenesis by inhibiting the factor Xa-PAR2-mediated suppression of macrophage autophagy and abrogating inflammasome activity.
Collapse
Key Words
- 7KC, 7-ketocholesterol
- ApoE–/–, apolipoprotein E deficient
- BSA, bovine serum albumin
- CAD, coronary artery disease
- CQ, chloroquine
- ELISA, enzyme-linked immunosorbent assay
- FBS, fetal bovine serum
- HFD, high-fat diet
- IL, interleukin
- NLRP3, NLR family pyrin domain containing 3
- PAR2, protease-activated receptor 2
- PB, phosphate buffer
- PBS, phosphate-buffered saline
- PLA, proximity ligation assay
- PT, prothrombin time
- WT, wild type
- atherosclerosis
- autophagy
- factor Xa
- inflammasome
- mTOR, mammalian target of rapamycin
- rivaroxaban
Collapse
Affiliation(s)
- Yusuke Ito
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.,Department of Cardiovascular Medicine, Tokyo Kyosai Hospital, Tokyo, Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Shun Nakagama
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yuka Shiheido-Watanabe
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Natsuko Tamura
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Tetsuo Sasano
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
9
|
Waku T, Hagiwara T, Tamura N, Atsumi Y, Urano Y, Suzuki M, Iwami T, Sato K, Yamamoto M, Noguchi N, Kobayashi A. NRF3 upregulates gene expression in SREBP2-dependent mevalonate pathway with cholesterol uptake and lipogenesis inhibition. iScience 2021; 24:103180. [PMID: 34667945 PMCID: PMC8506969 DOI: 10.1016/j.isci.2021.103180] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 09/18/2021] [Accepted: 09/22/2021] [Indexed: 02/07/2023] Open
Abstract
Lipids, such as cholesterol and fatty acids, influence cell signaling, energy storage, and membrane formation. Cholesterol is biosynthesized through the mevalonate pathway, and aberrant metabolism causes metabolic diseases. The genetic association of a transcription factor NRF3 with obesity has been suggested, although the molecular mechanisms remain unknown. Here, we show that NRF3 upregulates gene expression in SREBP2-dependent mevalonate pathway. We further reveal that NRF3 overexpression not only reduces lanosterol, a cholesterol precursor, but also induces the expression of the GGPS1 gene encoding an enzyme in the production of GGPP from farnesyl pyrophosphate (FPP), a lanosterol precursor. NRF3 overexpression also enhances cholesterol uptake through RAB5-mediated macropinocytosis process, a bulk and fluid-phase endocytosis pathway. Moreover, we find that GGPP treatment abolishes NRF3 knockdown-mediated increase of neutral lipids. These results reveal the potential roles of NRF3 in the SREBP2-dependent mevalonate pathway for cholesterol uptake through macropinocytosis induction and for lipogenesis inhibition through GGPP production. NRF3 upregulates gene expression of enzymes in the mevalonate pathway NRF3 induces SREBP2 gene expression and interacts with active SREBP2 proteins NRF3 reduces neutral lipid levels through GGPS1-mediated GGPP production NRF3 enhances cholesterol uptake through RAB5-mediated macropinocytosis
Collapse
Affiliation(s)
- Tsuyoshi Waku
- Laboratory for Genetic Code, Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, 1-3 Miyakodani, Tatara, Kyotanabe, Kyoto 610-0394, Japan
| | - Toru Hagiwara
- Laboratory for Genetic Code, Graduate School of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| | - Natsuko Tamura
- Laboratory for Genetic Code, Graduate School of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| | - Yuri Atsumi
- Laboratory for Genetic Code, Graduate School of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| | - Yasuomi Urano
- Systems Life Sciences Laboratory, Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, 1-3 Miyakodani, Tatara, Kyotanabe, Kyoto 610-0394, Japan
| | - Mikiko Suzuki
- Center for Radioisotope Sciences, Tohoku University Graduate School of Medicine, 2-1 Seiryo-cho, Aoba-ku, Sendai 980-8575 Japan
| | - Takuya Iwami
- Laboratory for Genetic Code, Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, 1-3 Miyakodani, Tatara, Kyotanabe, Kyoto 610-0394, Japan
| | - Katsuya Sato
- Laboratory for Genetic Code, Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, 1-3 Miyakodani, Tatara, Kyotanabe, Kyoto 610-0394, Japan
| | - Masayuki Yamamoto
- Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, 2-1 Seiryo-cho, Aoba-ku, Sendai 980-8575 Japan
| | - Noriko Noguchi
- Systems Life Sciences Laboratory, Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, 1-3 Miyakodani, Tatara, Kyotanabe, Kyoto 610-0394, Japan
| | - Akira Kobayashi
- Laboratory for Genetic Code, Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, 1-3 Miyakodani, Tatara, Kyotanabe, Kyoto 610-0394, Japan.,Laboratory for Genetic Code, Graduate School of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| |
Collapse
|
10
|
Kawaguchi K, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga R, Tamura N, Aruga T, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Toi M. 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Tamura N, Yoshinuma M, Yin X, Ida K, Suzuki C, Shoji M, Mukai K, Funaba H. A new multi-tracer pellet injection for a simultaneous study of low- and mid/high-Z impurities in high-temperature plasmas. Rev Sci Instrum 2021; 92:063516. [PMID: 34243592 DOI: 10.1063/5.0043495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 06/01/2021] [Indexed: 06/13/2023]
Abstract
A new multi-tracer technique in the Tracer-Encapsulated Solid Pellet (TESPEL) method has been developed in order to acquire simultaneously the information about the behaviors of various impurities, i.e., to study concurrently the behaviors of low- and mid/high-Z impurities in magnetically confined high-temperature plasmas. In this new technique, an inorganic compound (for example, lithium titanate, Li2TiO3) is proposed to be used as a tracer embedded in the core of the TESPEL, instead of pure elements. The results of the proof-of-principle experiment clearly demonstrate the applicability of the new multi-tracer technique in the TESPEL method for the simultaneous study of behaviors of low- and mid/high-Z impurities in high-temperature plasmas.
Collapse
Affiliation(s)
- N Tamura
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M Yoshinuma
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - X Yin
- University of South China, Hengyang, Hunan 421001, China
| | - K Ida
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - C Suzuki
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M Shoji
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K Mukai
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H Funaba
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| |
Collapse
|
12
|
Ono K, Kishimoto M, Fukui S, Kawaai S, Deshpande GA, Yoshida K, Ichikawa N, Kaneko Y, Kawasaki T, Matsui K, Morita M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Kobayashi S, Okada M, López-Medina C, Moltó A, Van der Heijde D, Dougados M, Komagata Y, Tomita T, Kaname S. POS0975 CLINICAL CHARACTERISTICS OF NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN ASIAN COUNTRIES COMPARED TO OTHER REGIONS: RESULTS OF THE INTERNATIONAL CROSS-SECTIONAL ASAS-COMOSPA STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Clinical characteristics of nonradiographic axial spondyloarthritis (nr-ax-SpA) are highly variable across patients, and may potentially vary across patient populations, particularly due to differing distributions of human leukocyte antigens (HLA) and other genetic factors. The majority of nr-ax-SpA studies have been conducted in Europe, the United States, and small studies are reported from Asia [1].Objectives:To delineate clinical characteristics of patients with nr-ax-SpA in Asian countries in comparison to other areas of the world.Methods:Utilizing the ASAS-COMOSPA data, an international cross-sectional observational study of SpA patients, we analyzed information on demographics, disease characteristics, comorbidities, and risk factors. Patients were classified by region: Asia (China, Japan, Singapore, South Korea, and Taiwan), and non-Asian countries (Europe, Americas, and Africa); patient characteristics, including diagnosis and treatment, were compared.Results:Among 3984 SpA patients included in the study, 1094 were from centers in Asian countries, and 2890 from other regions. 112/780 (14.4%) of axial SpA patients in Asian countries were nr-ax-SpA, substantially less than in other countries (486/1997, 24.3%). Nr-ax-SpA patients in Asian countries compared to nr-ax-SpA in other countries were more likely male (75.9 vs 47.1%), have onset (22.8 vs 27.8 years) and diagnosis (27.2 vs 34.5 years) at younger age, and experience less diagnostic delay (1.88 vs 2.92 years) (Table 1). Nr-ax-SpA patients in Asian countries have higher prevalence of positive HLA-B27 (90.6% vs 61.9%) and fewer peripheral signs such as arthritis, enthesitis, or dactylitis (53.6% vs 66.3%) but have similar rate of extra-articular manifestations (psoriasis, IBD, or uveitis) and co-morbidities. Disease activity, functional impairment, and inflammation on MRI were less in nr-ax-SpA patients in Asian countries. NSAIDs response was higher and use of methotrexate and b-DMARDs were lower among nr-ax-SpA in Asian countries.Conclusion:Among axial SpA patients, substantially lower frequency of nr-ax-SpA was observed in Asian countries compared to other regions of the world. Nr-ax-SpA patients in Asian countries were predominantly male, and had younger disease onset with higher HLA-B27 positivity rate and less peripheral signs, and better response to NSAIDs. These results offer an opportunity to improve both early diagnosis and treatment of nr-ax-SpA patients in Asian countries.Table 1.Characteristics of nonradiographic axial SpA in Asia versus non-Asian regionsVariablesAsianon-Asian regionsp valueN112486Age at disease diagnosis, yrs27.2 [21.1, 39.6]34.5 [27.7, 41.7]<0.001Diagnostic delay, yrs1.88 [0.27, 5.56]2.92 [0.59, 9.58]0.011Male (%)85 (75.9)229 (47.1)<0.001Sacroiliitis on MRI among tested (%)49 (67.1)341 (82.2)0.005HLA B27 positivity among measured (%)96 (90.6)273 (61.9)<0.001Inflammatory Back Pain (%)107 (95.5)478 (98.4)0.076Arthritis, enthesitis, or dactylitis (%)60 (53.6)322 (66.3)0.016Psoriasis (%)12 (10.7)82 (16.9)0.142Uveitis (%)20 (17.9)81 (16.7)0.870Inflammatory bowel disease (%)5 (4.5)27 (5.6)0.817Elevated CRP (%)37 (33.0)213 (43.8)0.048Physician global assessment (0-10)2.0 [1.0, 5.0]2.0 [1.0, 4.0]0.741Patient global assessment (0-10)3.0 [1.0, 6.0]4.0 [2.0, 6.0]0.012ASDAS-CRP1.40 [0.95, 2.08]1.97 [1.21, 2.78]<0.001BASFI0.8 [0.05, 2.65]2.9 [0.8, 5.6]<0.001Good response to NSAIDs (%)80 (71.4)272 (56.0)0.004Methotrexate use (%)18 (16.1)134 (27.6)0.016Biological DMARDs use (%)27 (24.1)191 (39.3)0.004References:[1]López-Medina C, Ramiro S, van der Heijde D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019 Nov 21;5(2): e001108.Acknowledgements:This study was conducted under the umbrella of the International Society for Spondyloarthritis Assessment (ASAS) and COMOSPA study was supported by unrestricted grants from Pfizer, AbbVie and UCB.Disclosure of Interests:Keisuke Ono: None declared, Mitsumasa Kishimoto Speakers bureau: AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB Pharma, Consultant of: AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB Pharma, Sho Fukui: None declared, Satoshi Kawaai: None declared, Gautam A. Deshpande: None declared, Kazuki Yoshida Consultant of: OM1, Inc., Grant/research support from: Corrona, LLC, Naomi Ichikawa: None declared, Yuko Kaneko Speakers bureau: AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB, Taku Kawasaki: None declared, Kazuo Matsui: None declared, Mitsuhiro Morita: None declared, Kurisu Tada: None declared, Naoho Takizawa: None declared, Naoto Tamura: None declared, Atsuo Taniguchi: None declared, Yoshinori Taniguchi: None declared, Shigeyoshi Tsuji: None declared, Shigeto Kobayashi: None declared, Masato Okada: None declared, Clementina López-Medina: None declared, Anna Moltó Consultant of: AbbVie, Pfizer, MSD, Novartis, Gilead, Lilly and UCB, Grant/research support from: AbbVie, Pfizer, MSD, Novartis, Gilead, Lilly and UCB, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma, Employee of: Imaging Rheumatology bv. (Director), Maxime Dougados: None declared, Yoshinori Komagata: None declared, Tetsuya Tomita: None declared, Shinya Kaname: None declared.
Collapse
|
13
|
Fujii T, Atsumi T, Okamoto N, Takahashi N, Tamura N, Nakajima A, Nakajima A, Matsuno H, Tsujimoto N, Nishikawa A, Ishii T, Takeuchi T, Kuwana M, Takagi M. AB0249 SAFETY OF BARICITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA): THE 2020 INTERIM REPORT FROM ALL-CASE POST MARKETING SURVEILLANCE IN CLINICAL PRACTICE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.433] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:An all-case post marketing surveillance (PMS) of baricitinib (Bari), that started in Sep 2017, collects safety and effectiveness for the first 24 wks of treatment and continues to collect serious adverse events (SAEs) for 3 yrs.Objectives:To evaluate Bari safety in RA patients (pt) in clinical practice.Methods:We report pt baseline demographics and adverse events (AEs) up to 24 wks for pts whose case report files for 24-wk data were completed as of Jun 2020.Results:Data from 3445 pts were analyzed (females=80%, mean age=64yr, mean RA duration 12yr). Bari dose regimen was as follows: 4mg, 60%, 2mg, 27%, 4mg→2mg, 5%, 2mg→4mg, 5%, and others, 2%. Concomitant use of MTX and glucocorticoid was 65% and 48%, respectively. 74% continued treatment for 24 wks. AE and SAE were recognized in 887 (26%) and 122 pts (4%), respectively. 6 pts died of pneumonia, aspiration pneumonia, bacterial pneumonia, cerebral infarction/ILD/aspiration pneumonia, adenocarcinoma, and colorectal cancer. Major AEs were as follows: herpes zoster=3%, liver dysfunction=3%, serious infection=1%, anemia=1%, hyperlipidemia=1%, malignancy=0.3%, interstitial pneumonia=0.2%, MACE=0.1%, and VTE=0.1%.Conclusion:Data do not show new safety concerns and encourage guideline-compliant use of Bari.Disclosure of Interests:Takao Fujii Speakers bureau: Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; Ono Pharmaceutical Co. Ltd., Consultant of: Asahikasei Pharma Corp, Grant/research support from: Asahikasei Pharma Corp; AbbVie Japan GK; Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Ono Pharmaceutical Co., Ltd., Tatsuya Atsumi Speakers bureau: AbbVie Japan GK; Astellas Pharma Inc.; Bristol-Myers Squibb Co. Ltd; Chugai Pharmaceutical Co. Ltd.; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., Consultant of: AbbVie Japan GK; AstraZeneca plc.; Boehringer Ingelheim Co. Ltd.; Medical & Biological Laboratories Co. Ltd.; Novartis Pharma K.K.; Ono Pharmaceutical Co. Ltd.; Pfizer Japan Inc., Grant/research support from: Astellas Pharma Inc., Alexion Inc.; Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Ltd.Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd., Nami Okamoto Speakers bureau: AbbVie Japan GK; Asahikasei Pharma Co.; AYUMI Pharmaceutical Co.Eisai Co. Ltd; Bristol-Myers Squibb Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Pfizer Japan Inc.Sanofi K.K.; Chugai Pharmaceutical Co. Ltd.; Novartis Pharma Co.; Teijin Pharma Ltd.; Torii Pharmaceutical Co., Ltd., Nobunori Takahashi Speakers bureau: AbbVie Japan GK; Eisai Co. Ltd.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; UCB Japan Co. Ltd.; Astellas Pharma Inc.; Bristol Myers Squibb Co. Ltd., Grant/research support from: Bristol Myers Squibb Co. Ltd., Naoto Tamura Speakers bureau: AbbVie Japan GK; Bristol Myers Squibb Co. Ltd.; Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Glaxo Smith Kline K.K.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co., Atsuo Nakajima: None declared, Ayako Nakajima Speakers bureau: AbbVie Japan GK; Actelion Pharmaceuticals Japan Ltd., Asahi Kasei Pharma Co., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd.,Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Glaxo Smith Kline K.K., Hisamitsu Pharmaceutical Co. Inc., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Teijin Pharma Ltd., Grant/research support from: Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Hiroaki Matsuno Speakers bureau: Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Consultant of: Mochida Pharmaceutical Co., Ltd., Grant/research support from: Astellas Pharma Inc., Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K, Naoto Tsujimoto Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Atsushi Nishikawa Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Taeko Ishii Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Tsutomu Takeuchi Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan K.K.; Gilead Sciences, Inc. Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co.; Pfizer Japan Inc.; Sanofi K.K.; UCB Japan Co., Ltd., Consultant of: AbbVie Japan GK, Astellas Pharma, Inc.; Chugai Pharmaceutical Co, Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Gilead Sciences, Inc.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Corp., Pfizer Japan Inc., Grant/research support from: AbbVie Japan GK, Asahikasei Pharma Corp., Chugai Pharmaceutical Co, Ltd., DNA Chip Research Inc.; Eisai Co., Ltd., Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp., UCB Japan Co., Ltd., Masataka Kuwana Speakers bureau: AbbVie Japan GK, Astellas Pharma Inc., Asahi Kasei Pharma Co., Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Medical &Biological Laboratories Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Pfizer Japan Inc., Consultant of: Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Corbus Pharmaceuticals Holdings, Inc.; Medical &Biological Laboratories Co., Ltd.; Mochida Pharmaceutical Co., Ltd., Grant/research support from: Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Medical &Biological Laboratories Co., Ltd; Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., Ltd., Michiaki Takagi Speakers bureau: Yes, but sponsored lectures without COI in the academic meetings, only.
Collapse
|
14
|
Nespoli F, Ashikawa N, Gilson E, Lunsford R, Masuzaki S, Shoji M, Oishi T, Suzuki C, Nagy A, Mollen A, Pablant N, Ida K, Yoshinuma M, Tamura N, Gates D, Morisaki T. First impurity powder injection experiments in LHD. Nuclear Materials and Energy 2020. [DOI: 10.1016/j.nme.2020.100842] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Tanaka A, Watanabe K, Kondo S, Tamura N, Nishimoto T, Yoshida Y. Purification of human iPSC-derived cardiomyocytes by HDAC inhibition through inducing apoptosis and cell arrest in non-cardiomyocytes. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Cell therapy is one of the most promising strategies for treatment of heart failure. During preparation of iPSC-derived cardiomyocytes for cells therapy, it is important to eliminate the presence of residual proliferative non-target cells in the preparation as these non-target cells could present the risk of tumorgenicity. To minimize the risk, selective and more precise purification process is necessary.
Purpose
We hypothesized that the differences in proliferative activity between cardiomyocytes and non-target cells might result in different sensitivities to the drugs targeting cell growth/survival. The aim of this study is to obtain compounds that eliminate non-cardiomyocytes selectively and to study the mechanism of action of these compounds.
Methods and results
We screened 314 small compounds using both iPSCs and sorted hiPSC-derived cardiomyocytes (hiPSC-CMs). We identified several compounds, which markedly decreased the cell numbers of iPSCs, but showed minimum effects on those of hiPSC-CMs. Among them, HDAC inhibitors were selected as the most promising candidates. We examined whether HDAC inhibitors could purify hiPSC-CMs containing non-cardiomyocytes populations, which were differentiated using the classical embryoid body (EB) method. As a result, HDAC inhibitors increased the purity of cardiomyocytes (up to 98%) by decreasing non-target cells such as smooth muscle cells, endothelial cells, and endodermal lineage cells. Moreover, we confirmed HDAC inhibitors could be used for purification of cardiomyocytes in monolayer differentiation protocol using GSK3β inhibitor and Wnt inhibitor. We measured the expression levels of mRNA and protein in iPSCs and hiPSC-CMs (EB method) treated with HDAC inhibitors. mRNA levels of CDKN1A (p21) and BAX were upregulated in iPSCs. Western blotting analyses revealed that HDAC inhibitors also induced the expression of p21 and the cleavage of Caspase3 in iPSCs.
Conclusions
Our result suggests that the inhibition of HDAC enables an efficient purification of hiPSC-CMs in multiple differentiation methods. Furthermore, our data indicate that HDAC inhibitors induce the apoptosis and cell cycle arrest in iPSCs but not hiPSC-CMs.
Figure 1
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Takeda Pharmaceutical Company Limited
Collapse
Affiliation(s)
- A Tanaka
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - K Watanabe
- Takeda Pharmaceutical Company Limited, Pharmaceutical Sciences, Fujisawa, Japan
| | - S Kondo
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - N Tamura
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - T Nishimoto
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - Y Yoshida
- Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| |
Collapse
|
16
|
Hall JG, Smith EF, Tamura N, Fakra SC, Bosak T. Preservation of erniettomorph fossils in clay-rich siliciclastic deposits from the Ediacaran Wood Canyon Formation, Nevada. Interface Focus 2020; 10:20200012. [PMID: 32637067 PMCID: PMC7333903 DOI: 10.1098/rsfs.2020.0012] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/28/2020] [Indexed: 11/12/2022] Open
Abstract
Three-dimensionally preserved Ediacaran fossils occur globally within sandstone beds. Sandy siliciclastic deposits of the Ediacaran Wood Canyon Formation (WCF) in the Montgomery Mountains, Nevada, contain two fossil morphologies with similar shapes and sizes: one exhibits mm-scale ridges and a distinct lower boundary and the other is devoid of these diagnostic features. We interpret these as taphomorphs of erniettomorphs, soft-bodied organisms with uncertain taxonomic affinities. We explore the cast-and-mould preservation of both taphomorphs by petrography, Raman spectroscopy, X-ray fluorescence microprobe and X-ray diffraction. All fossils and the surrounding sedimentary matrix contain quartz grains, iron-rich chlorite and muscovite. The ridged fossils contain about 70% larger quartz grains compared to the ridgeless taphomorph, indicating a lower abundance of clay minerals in the ridged fossil. Chlorite and muscovite likely originated from smectite and kaolinite precursors that underwent lower greenschist facies metamorphism. Kaolinite and smectite are inferred to have been abundant in sediments around the ridged fossil, which enabled the preservation of a continuous, distinct, clay- and kerogen-rich bottom boundary. The prevalence of quartz in the ridged fossils of the WCF and in erniettomorphs from other localities also suggests a role for this mineral in three-dimensional preservation of erniettomorphs in sandstone and siltstone deposits.
Collapse
Affiliation(s)
- J. G. Hall
- Department of Earth, Atmospheric, and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, USA
| | - E. F. Smith
- Department of Earth and Planetary Sciences, Johns Hopkins University, Baltimore, USA
| | - N. Tamura
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, USA
| | - S. C. Fakra
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, USA
| | - T. Bosak
- Department of Earth, Atmospheric, and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, USA
| |
Collapse
|
17
|
Abstract
Background:Japan is the world’s most aged country. The number of patients with polymyalgia rheumatic (PMR) is expected to increase more.Classification criteria including ultrasound findings were published in 2012(1), but the ability to differentiate PMR from other mimicking diseases was unknown.It is difficult to diagnose PMR accurately. We will clarify whether recently reported ultrasound findings (2, 3) which could be characteristic in PMR are helpful for distinguishing from other mimicking diseases and treatment outcome in suspected PMR patients. Neither diagnostic laboratory test nor specific antibody exist, and inflammatory markers such as C reactive protein and erythrocyte sedimentation rate are not specific.Objectives:Patients who were clinically suspected of PMR and underwent ultrasound examination from 2008 to 2018. And Patients who visited the hospital with PMR and were diagnosed with PMR from 2008 to 2018.Methods:Patients who visited the hospital and were diagnosed with PMR were extracted from the medical record database of the hospital. Patients who had been administrated GC at the first visit and whose records were not confirmed were excluded. Patients who were clinically diagnosed with PMR without ultrasound(Cli-PMR), patients who were diagnosed with PMR with ultrasound reports(US-Cli-PMR), patients who were diagnosed by the ultrasound expert only based on ultrasound images(US-PMR).Patient were followed up for one year. Clinical diagnoses were confirmed at the 6 months and 12 months since the first GC administration.Three groups were compared with each other in the rate of diagnosis change and the time intervals between the initiation of GC treatment and the occurrence of events: recurrence, methotrexate introduction and the normalization of C reactive protein.the Kaplan–Meier method was used to evaluate the outcomes. Statistical analyses were conducted with R software, version 3.5.2 (R Foundation for Statistical Computing) and EZR(4).Results:545 PMR patients were extracted. 403 of 545 was excluded because of preexisting GC therapy and record availability.At the 6 months follow-up, 92.8% of the non-US PMR group and 97% of US-PMR group remain PMR and at the 12 months follow-up 88.8% and 95% respectively. There was no significant difference in the three time-to-event outcomes.Conclusion:Ultrasound did not contribute the improvement of the PMR outcomes. However, this finding was affected by confounding factors for example assignment to ultrasound and atypical cases and rheumatologists’ uncertainness. Despite confounding factors, US-PMR group was not inferior. These findings showed that ultrasound may be useful for the complicated cases.References:[1]ARTHRITIS & RHEUMATISMVol. 64, No. 4, April 2012, pp 943–954[2]Clin Med Insights Arthritis Musculoskelet Disord 2017;10: 1179544117745851.[3]Biomed Res Int 2017;2017: 4272560.[4]Bone Marrow Transplantation 2013: 48, 452–458Disclosure of Interests:None declared
Collapse
|
18
|
Kawamoto T, Ogasawara M, Mastuki-Muramoto Y, Kawaguchi T, Ando S, Matsushita M, Yamanaka K, Yamaji K, Tamura N. SAT0262 PROPOSAL FOR OPTIMIZATION OF DIAGNOSTIC IMAGING FOR GIANT CELL ARTERITIS USING THREE-DIMENSIONAL COMPUTED TOMOGRAPHY ANGIOGRAPHY IMAGE AND CONSTRUCTING VASCULAR MAPPING FROM VASCULAR ULTRASONOGRAPHY AS REFERENCES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The development of rapid and accurate methods of diagnosing giant cell arteritis (GCA) is critical to prevent blindness and stroke, which may develop rapidly in patients with GCA. In 2018, EULAR published recommendations that the first imaging modality for GCA should be vascular ultrasonography without biopsy. However, many institutions still consider biopsy to make an important contribution to the diagnosis of GCA.Objectives:Our purpose is to eliminate blindness and stroke among GCA patients by optimizing diagnostic imaging and method to diagnose GCA employed by vascular ultrasonography (V-US), CT Angiography (CTA), MRI/A, and PET/CT without biopsy.Methods:We evaluated the clinical and serological characteristics of 20 patients who were diagnosed with GCA at our hospital from 2012 to 2018, and compared the image and biopsy findings of these patients. We then evaluated the effect of optimizing diagnostic imaging and methods for patients with suspected GCA who visited our hospital during 2019. Vascular mapping was carried out using V-US for 3DCTA and other imaging methods as references.Results:Table 1 shows the clinical characteristics of the study population. The sensitivity of CTA for GCA was 85.7% (12 of 14 patients), which was the highest of the studied imaging methods. All biopsy-positive cases were diagnosed as GCA, and we compared these cases with cases with positive imaging findings. This revealed that CTA findings were correct (i.e., positive) in 66.7% (four of six patients), MRI/A findings were correct in in 33.3% (three of nine), V-US findings were correct in 50.0% (three of six). Therefore, CTA exhibited the highest sensitivity for positive findings. Comparison of biopsy-positive cases with cases in which imaging findings were negative revealed that CTA findings were correct (negative) in 33.3% (two of six patients), MRI/A findings were correct in 55.6% (five of nine), V-US was correct in 50.0% (three of six). Thus, CTA had the lowest sensitivity for negative findings. Comparison of CTA findings of positive cases with other imaging modalities which reported positive findings revealed MRI/A findings to be correct in 44.4% (four of nine patients), PET/CT findings to be correct in 50.0% (one of two), V-US to be correct in 63.3% (five of eight). Thus, V-US had the highest agreement with CTA. We carried out vascular mapping by V-US using 3DCTA and other imaging methods and produced references to improve the accuracy of diagnosis. Using these references, we diagnosed five cases of GCA among the 20 patients; the positive predictive value of V-US was 80% (four of five patients) and negative predictive value was 86.7% (13 of 15 patients).Table 1.Baseline characteristics of the study sample The number of biopsies performed decreased from 50% (10 of 20 patients) from 2012 to 2018 to 15% (3 of 20 patients) in 2019. Two cases in the present study had positive findings in both biopsy and V-US; in one case, biopsy, CTA, and MRI/A were negative while V-US revealed positive findings. No patients with GCA developed blindness or stroke during 2019.Conclusion:We propose that V-US should be performed as the first examination for the diagnosis of GCA by the creation of vascular mappings when GCA is suspected in order to prevent blindness and stroke.References:[1]Christian Dejaco et al.EULAR recommendations for the use of imaging in large vasculitis in clinical practice.Annals of the Rheumatic Diseases,2018 May;77(5):636-643[2]Kawamoto T et al.Diagnosis of giant cell arthritis by head-contrast three-dimensional computed tomography angiography.Journal of Medical Case Reports2019 Sep 11;13(1):285.Figure 1.Left side is before, right side is after thrapy. (A) 3DCTA finding, (B) determination of V-US arrangement with vascular location to evaluate wall thickening of V-US, compression sign, stenosis and stoppage of vessels.Disclosure of Interests:None declared
Collapse
|
19
|
Abe Y, Kuga T, Kusaoi M, Tada K, Yamaji K, Tamura N. THU0337 THE EFFECTIVENESS OF PLASMA EXCHANGE THERAPY FOR ANTI-MDA5 ANTIBODY-POSITIVE REFRACTORY INTERSTITIAL LUNG DISEASE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:This is an extended report of our study [1]. Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, which are closely related to interstitial lung disease (ILD) with or without rapid progression, are a type of myositis-specific autoantibody. Since rapid progressive-ILD (RP-ILD) with anti-MDA5 antibodies is refractory and fatal, intensive immunosuppressive therapy with combination calcineurin inhibitor, and intravenous pulse cyclophosphamide was developed, and was shown to improve patient survival and prognosis [2]. However, 20–30% of cases were still fatal, and several additional therapies have been reported e.g. tofacitinib [3] and plasma exchange therapy (PE) [1, 4, 5].Objectives:We evaluated the effect of plasma exchange (PE) on survival in patients with refractory RP-ILD who were positive for anti-MDA5 antibodies.Methods:Among 167 patients newly diagnosed with PM/DM, clinically amyopathic DM, or cancer associated myositis from 2008 to 2019 at our hospital, 12 were diagnosed with refractory RP-ILD and were positive for anti-MDA5 antibodies. PE was used as an adjunct to standard therapy and consisted of fresh frozen plasma as replacement solution. The primary outcome was non-disease-specific mortality. anti-MDA5 antibody titres were measured by ELISA using the MESACUP anti-MDA5 test in 155 patients whose serum was frozen and stored at the time of diagnosis.Results:Anti-MDA5 antibodies were detected in 35 patients, of whom 26 were diagnosed with RP-ILD and 11 were refractory to intensive immunosuppressive therapy. Seven patients received PE (PE group) and four did not (non-PE group). The 1-year survival rate of the PE group was higher than that of the non-PE group (100% and 25%, respectively, P = 0.011). Regarding adverse events associated with PE, two patients had anaphylactic shock, one had high fever due to fresh frozen plasma allergy and one had a catheter infection. All adverse events resolved with appropriate treatment.Conclusion:We evaluated the association between 1-year survival rate and PE for refractory RP-ILD in patients positive for anti-MDA5 antibodies. Intensive immunosuppressive therapy improved the survival rate in RP-ILD patients with anti-MDA5 antibodies, but 20-30% of cases were still fatal. PE could be administered to patients with active infectious disease who were immunocompromised by intensive immunosuppressive therapy. PE may be considered in refractory RP-ILD patients positive for anti-MDA5 antibodies.References:[1]Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25:925-33.[2]Kurasawa K, Arai S, Namiki Y et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018;57:2114-9.[3]Silveira MG, Selva-O’Callaghan A, Ramos-Terrades N et al. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM. 2016;109:49-50.[4]Endo Y, Koga T, Suzuki T et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report. Medicine (Baltimore). 2018;97:e0436.[5]Abe Y, Kusaoi M, Tada K et al. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology. 2019.Acknowledgments:Funding: This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Number JP18K15433.Disclosure of Interests:None declared
Collapse
|
20
|
Kuga T, Matsushita M, Tada K, Yamaji K, Tamura N. AB0422 LEFT VENTRICULAR ABNORMALITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FOLLOWED BY SEQUENTIAL ECHOCARDIOGRAPHY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Cardiovascular disease (CVD) is detected in up to 50% of systemic lupus erythematosus (SLE) patients1and major cause of death2. Even clinically silent SLE patients can develop left ventricular (LV) diastolic dysfunction3. Proper echocardiographic follow up of SLE patients is required.Objectives:To clarify how the prevalence of LV abnormalities changes over follow-up period and identify the associated clinical factors, useful in suspecting LV abnormalities.Methods:29 SLE patients (24 females and 5 men, mean age 52.8±16.3 years, mean disease duration 17.6±14.5 years) were enrolled. All of them underwent echocardiography as the baseline examination and reexamined over more than a year of follow-up period(mean 1075±480 days) from Jan 2014 to Sep 2019. Patients complicated with pulmonary artery hypertension, deep venous thrombosis or pulmonary embolism and underwent cardiac surgery during the follow-up period were excluded. Left ventricular(LV) systolic dysfunction was defined as ejection fraction (EF) < 50%. LV diastolic dysfunction was defined according to ASE/EACVI guideline4. LV dysfunction (LVD) includes one or both of LV systolic dysfunction and LV diastolic function. Monocyte to HDL ratio (MHR) was calculated by dividing monocyte count with HDL-C level.Prevalence of left ventricular abnormalities was analysed at baseline and follow-up examination. Clinical characteristics and laboratory data were compared among patient groups as follows; patients with LV dysfunction (Group A) and without LV dysfunction (Group B) at the follow-up echocardiography, patients with LV asynergy at any point of examination (Group C) and patients free of LV abnormalities during the follow-up period (Group D).Results:At the baseline examination, LV dysfunction (5/29 cases, 13.8%), LV asynergy (6/29 cases, 21.7%) were detected. Pericarditis was detected in 7 patients (24.1%, LVD in 3 patients, LV asynergy in 2 patients) and 2 of them with subacute onset had progressive LV dysfunction, while 5 patients were normal in echocardiography after remission induction therapy for SLE. At the follow-up examination, LV dysfunction (9/29 cases, 31.0%, 5 new-onset and 1 improved case), LV asynergy (6/29 cases, 21.7%, 2 new-onset and 2 improved cases) were detected. Though any significant differences were observed between Group A and Group B at the baseline, platelet count (156.0 vs 207.0, p=0.049) were significantly lower in LV dysfunction group (Group A) at the follow-up examination. Group C patients had significantly higher uric acid (p=0.004), monocyte count (p=0.009), and MHR (p=0.003) than Group D(results in table).Conclusion:LV dysfunction is progressive in most of patients and requires regular follow-up once they developed. Uric acid, monocyte count and MHR are elevated in SLE patients with LV asynergy. Since MHR elevation was reported as useful marker of endothelial dysfunction5, our future goal is to analyse involvement of monocyte activation and endothelial dysfunction in LV asynergy of SLE patients.References:[1]Doria A et al. Lupus. 2005;14(9):683-6.[2]Manger K et al. Ann Rheum Dis. 2002 Dec;61(12):1065-70.[3]Leone P et al. Clin Exp Med. 2019 Dec 17.[4]Nagueh SF et al. J Am Soc Echocardiogr. 2016 Apr;29(4):277-314.[5]Acikgoz N et al. Angiology. 2018 Jan;69(1):65-70.Numbers are median (interquartile range), Mann-Whitney u test were performed, p value less than 0.05 was considered statistically significant.Disclosure of Interests: :None declared
Collapse
|
21
|
Matsushita M, Amano H, Nozawa K, Ogasawara M, Tada K, Kempe K, Kusaoi M, Kawamoto T, Minowa K, Ando S, Nemoto T, Abe Y, Hayashi E, Murayama G, Tsukahara T, Yamanaka K, Morimoto S, Yang K, Matsudaira R, Katagiri A, Nakiri Y, Takasaki Y, Yamaji K, Tamura N. FRI0179 A STUDY ON THE ACHIEVEMENT OF LUPUS LOW DISEASE ACTIVITY STATE AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: FROM THE JUNTENDO UNIVERSITY SLE PROSPECTIVE REGISTRY STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology that affects mostly young women. Multiorgan complications and prolonged treatment significantly cause physical and mental stress in patients. Improving patients’ quality of life (QOL) in SLE treatment is essential. We examined the treatment effects on disease activity and QOL of SLE patients.Objectives:In recent years, lupus low disease activity state (LLDAS) has been proposed as a treatment target for SLE. Patients who achieve LLDAS have a low recurrence rate for lupus and a low risk of serious complications (1). The aim of this study is to investigate whether achieving LLDAS reduces not only recurrence rate and complications of SLE but also improves patients’ QOL.Methods:A total of 104 SLE patients were enrolled in our prospective SLE registry study (Juntendo, Multi-center, Prospective cohort for investigation of clinical course and outcome in SLE: JUMP) conducted at our institution. SLE was diagnosed using the American College of Rheumatology (ACR) 1982 criteria (revised in 1997). QOL was evaluated using the standard version of the 36-item short form health survey version 2 (SF36v2). Participants were divided into the LLDAS achievement and non-achievement groups, and the characteristics of each group including results of SF36v2 were examined.Results:This study included 104 SLE patients, 94 female and 10 male, and the average age and disease duration were 46.4±13.8 and 14.5±11.3 years, respectively. The average corticosteroid dose was 8.0±17.4 mg/day in terms of prednisolone, and anti-dsDNA antibody titer was 16.8±38.5 IU/ml. Of the 104 patients, 57 achieved LLDAS. The subscale’s standard scoring using SF36v2 for role physical (RP) was 78.9±24.0 and 64.6±27.6 (P<0.01), general health (GH) was 50.0±17.0 and 42.0±19.3 (P<0.05), vitality (VT) was 55.8±15.8 and 38.0±24.1 (P<0.01), social functioning (SF) was 82.0±20.7 and 66.5±26.3 (P<0.01), role emotional (RE) was 89.0±16.1 and 73.4±28.1 (P<0.01), and mental health (MH) was 72.4±15.9 and 58.3±21.8 (P<0.01) in the LLDAS achievement and non-achievement groups, respectively. Furthermore, scoring based on the national standard value in the LLDAS achievement group showed that two categories were >50. However, in the LLDAS non-achievement group, all categories were <50. In particular, RP, GH, VT, SF, RE, and MH of the LLDAS achievement group had significantly higher scores than the LLDAS non-achievement group (RP and GH: p<0.05 and VT, SF, RE and MH: p<0.01).Conclusion:Results of examining the association between LLDAS and QOL using SF36v2 in SLE patients showed that patients who achieved LLDAS had significantly better standard statistical scores in many subscale categories. Thus, LLDAS achievement as a treatment target for SLE patients greatly contributes to improving patients’ QOL.References:[1]Franklyn K, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).Ann Rheum Dis. 2016 Sep;75(9):1615-21.Disclosure of Interests:None declared
Collapse
|
22
|
Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, Nishi R, Koike H, Kaida K, Koga M, Kanda T, Ogata H, Kira JI, Mori M, Kuwabara S, Katsuno M. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Res Protoc 2020; 9:e17117. [PMID: 32234705 PMCID: PMC7160709 DOI: 10.2196/17117] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 01/27/2020] [Accepted: 01/27/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated peripheral neuropathy that is currently classified into several clinical subtypes, which are presumed to have different pathogenic mechanisms. Recently, studies identified a subgroup of patients with CIDP who were positive for IgG4 autoantibodies against paranodal proteins, such as neurofascin-155 and contactin-1, who respond poorly to first-line therapies for typical CIDP, including intravenous immunoglobulin therapy. OBJECTIVE This study aims to evaluate the efficacy and safety of intravenous rituximab according to IgG4 autoantibody status in patients with refractory CIDP. METHODS The Evaluation of the Efficacy and Safety of Rituximab in Refractory CIDP Patients with IgG4 Autoantibodies in the Exploratory Clinical (RECIPE) trial consists of 2 cohorts: a multicenter, placebo-controlled, randomized study cohort of 15 patients with IgG4 autoantibody-positive CIDP (rituximab:placebo = 2:1) and an open-label trial cohort of 10 patients with antibody-negative CIDP. The primary endpoint is improvement in functional outcome assessed using the adjusted Inflammatory Neuropathy Cause and Treatment Disability Scale score at 26, 38, or 52 weeks after the start of treatment with rituximab in patients with CIDP and anti-paranodal protein antibodies. Secondary outcome measures include grip strength, manual muscle testing sum scores, results of nerve conduction studies, and other functional scales. RESULTS We plan to enroll 25 cases for the full analysis set. Recruitment is ongoing, with 14 patients enrolled as of January 2020. Enrollment will close in September 2020, and the study is planned to end in December 2021. CONCLUSIONS This randomized controlled trial will determine if rituximab is safe and effective in patients with anti-paranodal antibodies. An open-label study will provide additional data on the effects of rituximab in patients with antibody-negative CIDP. The results of the RECIPE trial are expected to provide evidence for the positioning of rituximab as a pathogenesis-based therapeutic for refractory CIDP. TRIAL REGISTRATION ClinicalTrials.gov NCT03864185, https://clinicaltrials.gov/ct2/show/NCT03864185 ; The Japan Registry of Clinical Trials jRCT2041180037, https://jrct.niph.go.jp/en-latest-detail/jRCT2041180037. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/17117.
Collapse
Affiliation(s)
- Shinobu Shimizu
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Masahiro Iijima
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.,Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuki Fukami
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Natsuko Tamura
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.,Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima, Japan
| | - Masahiro Nakatochi
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.,Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masahiko Ando
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Ryoji Nishi
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Haruki Koike
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Kenichi Kaida
- Department of Neurology, Anti-aging and Vascular Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Michiaki Koga
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - Takashi Kanda
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - Hidenori Ogata
- Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Jun-Ichi Kira
- Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Masahiro Mori
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Satoshi Kuwabara
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Masahisa Katsuno
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
23
|
Tamura N, Maejima Y, Matsumura T, Vega RB, Amiya E, Ito Y, Shiheido-Watanabe Y, Ashikaga T, Komuro I, Kelly DP, Hirao K, Isobe M. Single-Nucleotide Polymorphism of the MLX Gene Is Associated With Takayasu Arteritis. Circ Genom Precis Med 2019; 11:e002296. [PMID: 30354298 DOI: 10.1161/circgen.118.002296] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Takayasu arteritis (TAK) is an autoimmune systemic arteritis of unknown pathogenesis. Genome-wide association studies revealed that single-nucleotide polymorphisms in the MLX gene encoding the MLX (Max-like protein X) transcription factor are significantly associated with TAK in Japanese patients. MLX single-nucleotide polymorphism rs665268 is a missense mutation causing the Q139R substitution in the DNA-binding site of MLX. METHODS To elucidate the hypothesis that the single-nucleotide polymorphism of the MLX gene plays a critical role in the development of TAK, we conducted clinical and laboratory analyses. RESULTS We show that rs665268 significantly correlated with the severity of TAK, including the number of arterial lesions and morbidity of aortic regurgitation; the latter may be attributed to the fact that MLX mRNA expression was mostly detected in the aortic valve. Furthermore, the Q139R mutation caused structural changes in MLX, which resulted in enhanced formation of a heterodimer with MondoA, upregulation of TXNIP (thioredoxin-interacting protein) expression, and increase in the activity of the NLRP3 (NACHT, LRR, and PYD domains-containing protein 3) inflammasome and cellular oxidative stress. Furthermore, autophagy, which negatively regulates inflammasome activation, was suppressed by the Q139R mutation in MLX. The MLX-Q139R mutant significantly induced macrophage proliferation and macrophage-endothelium interaction, which was abolished by the treatment with SBI-477, an inhibitor of MondoA nuclear translocation. Our findings suggest that the Q139R substitution in MLX plays a crucial role in the pathogenesis of TAK. CONCLUSIONS MLX-Q139R mutation plays a crucial role in the pathogenesis of TAK through promoting inflammasome formation.
Collapse
Affiliation(s)
- Natsuko Tamura
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.)
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.)
| | - Takayoshi Matsumura
- Department of Cardiovascular Medicine, The University of Tokyo, Japan (T.M., E.A., I.K.)
| | - Rick B Vega
- Translational Research Institute for Diabetes and Metabolism, Florida Hospital, Orlando (R.B.V.)
| | - Eisuke Amiya
- Department of Cardiovascular Medicine, The University of Tokyo, Japan (T.M., E.A., I.K.)
| | - Yusuke Ito
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.)
| | - Yuka Shiheido-Watanabe
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.)
| | - Takashi Ashikaga
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.)
| | - Issei Komuro
- Department of Cardiovascular Medicine, The University of Tokyo, Japan (T.M., E.A., I.K.)
| | - Daniel P Kelly
- Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.P.K.)
| | - Kenzo Hirao
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.)
| | - Mitsuaki Isobe
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan (N.T., Y.M., Y.I., Y.S.-W., T.A., K.H., M.I.).,Sakakibara Heart Institute, Japan Research Promotion Society for Cardiovascular Diseases, Tokyo (M.I.)
| |
Collapse
|
24
|
Tamura N, Fujiwara Y, Hashimoto T, Shiraishi H, Kitano S, Shimizu T, Yamamoto N, Motoi N. Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz072.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Ozaki Y, Takahashi M, Tanabe Y, Miura Y, Tamura N, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T. Atypical femoral fracture in breast cancer patients with bone metastasis receiving denosumab therapy: multi-center retrospective analysis. Breast 2019. [DOI: 10.1016/s0960-9776(19)30450-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
26
|
Jo H, Horinouchi H, Higashiyama R, Tamura N, Yagishita S, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy after Nivolumab in Patients With Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Kobayashi D, Asai T, Yamada S, Ishikawa Y, Tamura N, Narushima Y. Development of a tracer-containing compact-toroid injection system. Rev Sci Instrum 2018; 89:10I111. [PMID: 30399862 DOI: 10.1063/1.5039310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 07/08/2018] [Indexed: 06/08/2023]
Abstract
The accumulation and behavior of impurities is one of the most important subjects in the development of magnetically confined fusion reactors because impurities can potentially cause cooling and worsen the confinement of the hot core plasma. Tracer-encapsulated solid pellets (TESPELs) have demonstrated some results for impurity injection for fusion-reactor plasma studies [N. Tamura et al., J. Phys. Conf. Ser. 823, 012003 (2017)]. However, the TESPEL technique has several shortcomings, for example, the penetration depth and the amounts of tracer impurities. In the present study, we have developed a tracer-containing, compact-toroid (TCCT) injection system that utilizes a magnetized coaxial plasma gun (MCPG). The discharge current through the MCPG sputters and ionizes the electrode material, and the Lorenz self-force accelerates it as a plasmoid. The MCPG easily accelerates a magnetized plasmoid to speeds greater than the ion thermal velocity of several tens of kilometers per second. The accelerated and ejected plasmoid that contains the tracer ions is itself a warm, ionized plasma. Therefore, a TCCT can potentially be injected into the core region of a target plasma with less adverse effect.
Collapse
Affiliation(s)
- D Kobayashi
- Department of Physics, College of Science and Technology, Nihon University, Tokyo 101-8308, Japan
| | - T Asai
- Department of Physics, College of Science and Technology, Nihon University, Tokyo 101-8308, Japan
| | - S Yamada
- Department of Physics, College of Science and Technology, Nihon University, Tokyo 101-8308, Japan
| | - Y Ishikawa
- Department of Physics, College of Science and Technology, Nihon University, Tokyo 101-8308, Japan
| | - N Tamura
- National Institute for Fusion Science, Gifu 509-5292, Japan
| | - Y Narushima
- National Institute for Fusion Science, Gifu 509-5292, Japan
| |
Collapse
|
28
|
Bussiahn R, Tamura N, McCarthy KJ, Burhenn R, Hayashi H, Laube R, Klinger T. Tracer-Encapsulated Solid Pellet (TESPEL) injection system for Wendelstein 7-X. Rev Sci Instrum 2018; 89:10K112. [PMID: 30399711 DOI: 10.1063/1.5038844] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Accepted: 06/13/2018] [Indexed: 06/08/2023]
Abstract
Impurity confinement in fusion plasmas is mainly determined by transport mechanisms in the core region. For the Wendelstein 7-X stellarator, its island divertor is expected to screen effectively external impurity sources in the scrape-off layer at higher densities. However, the unique feature of Tracer-Encapsulated Solid Pellet (TESPEL) injection, releasing impurities at a well-localized radial position directly in the core plasma, enables investigating such transport mechanisms. This paper reports on the detailed design of a completely new TESPEL injection system, which has been designed by the National Institute for Fusion Science, Toki, Japan, and is currently being installed at Max-Planck-Institut für Plasmaphysik, Greifswald, Germany, for the Wendelstein 7-X. This injector consists of a storage and injection unit, attached to a system of guiding tubes which run through 3 successive differential pumping stages. A light-gate system and an optical observation system are used to determine the location of the deposited tracers. Laboratory tests carried out by shooting TESPELs onto a sample foil showed good performance after careful realignment of the guiding tubes.
Collapse
Affiliation(s)
- R Bussiahn
- Max-Planck-Institut für Plasmaphysik, Greifswald, Germany
| | - N Tamura
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Japan
| | - K J McCarthy
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain
| | - R Burhenn
- Max-Planck-Institut für Plasmaphysik, Greifswald, Germany
| | - H Hayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Japan
| | - R Laube
- Max-Planck-Institut für Plasmaphysik, Greifswald, Germany
| | - T Klinger
- Max-Planck-Institut für Plasmaphysik, Greifswald, Germany
| |
Collapse
|
29
|
Tamura N, Kodaira K, Yoshihara E, Mae N, Yamazaki Y, Mita H, Kuroda T, Fukuda K, Tomita A, Kasashima Y. A retrospective cohort study investigating risk factors for the failure of Thoroughbred racehorses to return to racing after superficial digital flexor tendon injury. Vet J 2018; 235:42-46. [DOI: 10.1016/j.tvjl.2018.03.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 03/06/2018] [Accepted: 03/10/2018] [Indexed: 10/17/2022]
|
30
|
Ito Y, Maejima Y, Tamura N, Shiheido-Watanabe Y, Konishi M, Ashikaga T, Hirao K, Isobe M. Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure. FEBS Open Bio 2018; 8:799-816. [PMID: 29744294 PMCID: PMC5929928 DOI: 10.1002/2211-5463.12416] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 02/15/2018] [Accepted: 03/12/2018] [Indexed: 01/19/2023] Open
Abstract
5-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) have beneficial effects in patients with heart failure (HF), regardless of serum cholesterol levels. However, their synergic effects with angiotensin II receptor blocker (ARB) remain to be established. We assessed the existence and potential underlying mechanisms of the effects of combined ARB [losartan (LOS)] and statin [simvastatin (SIM)] on cardiac function in rats and mice with load-induced HF. Salt-loaded Dahl salt-sensitive (DS) rats were treated with vehicle, LOS, SIM, or LOS + SIM for 8 weeks. To mimic load-induced HF in vitro, cultured neonatal rat cardiomyocytes (NRCM) were cyclically stretched. We also investigated the effect of LOS + SIM on pressure overload-induced HF using mice with transverse aortic constriction (TAC). LOS + SIM improved left ventricular (LV) function and reduced LV hypertrophy more than the monotherapies in both salt-loaded DS rats and TAC-operated mice. LV-tissue increases in Rho kinase and matrix metalloproteinase-9 activity were decreased to a greater extent by LOS + SIM than by LOS and SIM monotherapies. Plasma levels of Exp-3174, a LOS metabolite, were higher in LOS + SIM-treated DS rats than in LOS-treated rats. Stretch-induced hypertrophy of NRCM pretreated with SIM + Exp-3174 was significantly attenuated from that with LOS, Exp-3174, SIM, or LOS + SIM. SIM administration significantly enhanced mitophagy in mouse hearts after TAC. However, LOS + SIM reduced mitophagy, and the salutary effect of SIM in mouse hearts after TAC was abolished in AT1R-/- mice. In conclusion, LOS and SIM have beneficial myocardial effects on load-induced HF via differential pleiotropic effects. Thus, combination therapy of these drugs thus has potential as a therapeutic strategy for HF.
Collapse
Affiliation(s)
- Yusuke Ito
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Natsuko Tamura
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | | | - Masanori Konishi
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Takashi Ashikaga
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Kenzo Hirao
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Mitsuaki Isobe
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan.,Department of Cardiology Sakakibara Heart Institute Tokyo Japan
| |
Collapse
|
31
|
Inoue M, Nakamura T, Shigeno K, Ueda H, Tamura N, Fukuda S, Liu Y, Nakahara T, Toba T, Yoshitani M, Iizuka T, Shimizu Y. Regeneration of the Junctional Epithelium and Connective Tissue after Transplantation of Detergent-Processed Allo-Teeth. Int J Artif Organs 2018. [DOI: 10.1177/039139880002301211] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The authors have developed a new artificial dental implant and evaluated it in a dog model in terms of its potential to produce: I) regeneration of junctional epithelium; II) regeneration and attachment of connective tissue. The implants were constructed from allo-teeth. We removed the cell components from the periodontal ligaments of these teeth with a detergent (1% TritonX-100); the remaining acellular periodontal ligament acted as an extracellular matrix upon which regeneration and attachment could proceed. We placed 10 of these implants in the just-extracted sites of three beagle dogs. We observed regeneration of both junctional epithelium and connective tissue at all implant sites after 3 months. The connective tissue was attached in all cases. Use of the acellular periodontal ligament as an extracellular matrix may facilitate regeneration of host periodontal ligament tissue, thus contributing to recovery of host immunological defense and long-term oral function.
Collapse
Affiliation(s)
- M. Inoue
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kyoto University, Kyoto - Japan
| | - T. Nakamura
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - K. Shigeno
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - H. Ueda
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - N. Tamura
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - S. Fukuda
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - Y. Liu
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - T. Nakahara
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - T. Toba
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - M. Yoshitani
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - T. Iizuka
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kyoto University, Kyoto - Japan
| | - Y. Shimizu
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| |
Collapse
|
32
|
Nakamura T, Teramachi M, Sekine T, Kawanami R, Fukuda S, Yoshitani M, Toba T, Ueda H, Hori Y, Inoue M, Shigeno K, Taka TN, Liu Y, Tamura N, Shimizu Y. Artificial Trachea and Long Term follow-up in Carinal Reconstruction in Dogs. Int J Artif Organs 2018. [DOI: 10.1177/039139880002301010] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We have already reported “del” successful carinal reconstruction of the trachea with an observation period of 1 – 2 years. In this study, we evaluate the long-term safety and efficacy of the reconstruction after 5-years of follow-up. The Y-shaped Marlex® mesh tube was reinforced with a polypropylene spiral and coated with atelocollagen made from porcine skin. The prosthesis was 60 mm long with an outer diameter of 18 mm. Replacement of the tracheobronchial bifurcation was preformed through a right thoracotomy in a beagle dog. Bronchoscopical examination and sampling of the tracheal epithelium was performed periodically to check the function of cilia. The implanted prothesis was promptly infiltrated by the surrounding connective tissue and completely incorporated by the host trachea and bronchus. Bronchoscopically, sufficient epithelization was confirmed from the upper to the lower site of anastomosis. After 5 years neither stenosis nor dehiscence was observed. In spite of there being mesh-exposure at the luminal surface, the dog had no clinical symptoms until sacrifice for pathological examination. The bent frequency of the cilia was maintained within the normal range, indicating “del” functional recovery of the regenerating airway. Our tracheal prosthesis is promising for clinical “del” repair of the tracheobronchial bifurcation.
Collapse
Affiliation(s)
- T. Nakamura
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - M. Teramachi
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - T. Sekine
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - R. Kawanami
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - S. Fukuda
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - M. Yoshitani
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - T. Toba
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - H. Ueda
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - Y. Hori
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - M. Inoue
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - K. Shigeno
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - T. Nakahara Taka
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - Y. Liu
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - N. Tamura
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| | - Y. Shimizu
- Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto - Japan
| |
Collapse
|
33
|
Hirose K, Nishio K, Tanaka S, Léguillon R, Makii H, Nishinaka I, Orlandi R, Tsukada K, Smallcombe J, Vermeulen MJ, Chiba S, Aritomo Y, Ohtsuki T, Nakano K, Araki S, Watanabe Y, Tatsuzawa R, Takaki N, Tamura N, Goto S, Tsekhanovich I, Andreyev AN. Role of Multichance Fission in the Description of Fission-Fragment Mass Distributions at High Energies. Phys Rev Lett 2017; 119:222501. [PMID: 29286806 DOI: 10.1103/physrevlett.119.222501] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Indexed: 06/07/2023]
Abstract
Fission-fragment mass distributions were measured for ^{237-240}U, ^{239-242}Np, and ^{241-244}Pu populated in the excitation-energy range from 10 to 60 MeV by multinucleon transfer channels in the reaction ^{18}O+^{238}U at the Japan Atomic Energy Agency tandem facility. Among them, the data for ^{240}U and ^{240,241,242}Np were observed for the first time. It was found that the mass distributions for all the studied nuclides maintain a double-humped shape up to the highest measured energy in contrast to expectations of predominantly symmetric fission due to the washing out of nuclear shell effects. From a comparison with the dynamical calculation based on the fluctuation-dissipation model, this behavior of the mass distributions was unambiguously attributed to the effect of multichance fission.
Collapse
Affiliation(s)
- K Hirose
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - K Nishio
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - S Tanaka
- Faculty of Science and Engineering, Kindai University, Higashi-Osaka 577-8502, Japan
| | - R Léguillon
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - H Makii
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - I Nishinaka
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - R Orlandi
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - K Tsukada
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - J Smallcombe
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M J Vermeulen
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - S Chiba
- Laboratory for Advanced Nuclear Energy, Institute for Innovative Research, Tokyo Institute of Technology, 2-12-1-N1-19, Ookayama, Meguro-ku, Tokyo 152-8550 Japan
| | - Y Aritomo
- Faculty of Science and Engineering, Kindai University, Higashi-Osaka 577-8502, Japan
| | - T Ohtsuki
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - K Nakano
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Fukuoka 816-8580, Japan
| | - S Araki
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Fukuoka 816-8580, Japan
| | - Y Watanabe
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Fukuoka 816-8580, Japan
| | - R Tatsuzawa
- Graduate School of Engineering, Tokyo City University, Tokyo 158-8557, Japan
| | - N Takaki
- Graduate School of Engineering, Tokyo City University, Tokyo 158-8557, Japan
| | - N Tamura
- Graduate School of Science and Technology, Niigata University, Niigata 950-2181, Japan
| | - S Goto
- Graduate School of Science and Technology, Niigata University, Niigata 950-2181, Japan
| | - I Tsekhanovich
- University of Bordeaux, 351 Cours de la Libration, 33405 Talence Cedex, France
| | - A N Andreyev
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
- Department of Physics, University of York, York YO10 5DD, United Kingdom
| |
Collapse
|
34
|
Tamura N, Horinouchi H, Sekine K, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Efficacy of subsequent cytotoxic chemotherapy after nivolumab for patients with advanced non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Onoue H, Murakami K, Yoshizawa K, Yokota T, Norimine S, Akaiwa Y, Kamiya F, Ogawa T, Kamiya T, Hara M, Takiguchi Y, Numahata K, Yamaguchi Y, Tamura N, Miyamoto T. Successful amyotrophic lateral sclerosis treated with edaravone circle support network building from Dokkyo Medical University Koshigaya hospital (Successful allstar net from DMUK). J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Tamura N, Maejima Y, Tezuka D, Takamura C, Yoshikawa S, Ashikaga T, Hirao K, Isobe M. Profiles of serum cytokine levels in Takayasu arteritis patients: Potential utility as biomarkers for monitoring disease activity. J Cardiol 2017; 70:278-285. [DOI: 10.1016/j.jjcc.2016.10.016] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 10/24/2016] [Accepted: 10/28/2016] [Indexed: 01/28/2023]
|
37
|
Goto S, Tamura N, Ayabe K, Goto S. P3976The dominant parameters to determine the growth of arterial thrombi at site of endothelial injuries. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Maejima Y, Ito Y, Tamura N, Konishi M, Isobe M. P681Blood coagulation factor Xa promotes the progression of atherosclerosis by enhancing inflammasome formation as a consequence of PAR2-mediated autophagy inhibition. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Nakamura Y, Tamura N, Kobayashi M, Yoshimura S, Suzuki C, Yoshinuma M, Goto M, Motojima G, Nagaoka K, Tanaka K, Sakamoto R, Peterson B, Ida K, Osakabe M, Morisaki T. A comprehensive study on impurity behavior in LHD long pulse discharges. Nuclear Materials and Energy 2017. [DOI: 10.1016/j.nme.2016.11.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Ito H, Hayashi F, Nagao K, Takahashi N, Kobayashi Y, Kanazawa T, Yukawa H, Shimamura K, Tamura N, Kobayashi T, Kajitani K, Nakagawa E, Makita T, Inada T, Tanaka M. P4363Coronary flow reserve predicts improvement in left ventricular diastolic function after treatment in patients with impaired glucose tolerance. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Goto S, Tamura N, Ayabe K, Goto S. P4349A method for precision prediction of platelet adhesion at site of endothelial injury under blood flow conditions. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Maejima Y, Ito Y, Tamura N, Konishi M, Hirao K, Isobe M. Abstract 358: Factor Xa Deteriorates Atherosclerosis by Facilitating Inflammasome Formation via PAR-2-mediated Autophagy Suppression. Circ Res 2017. [DOI: 10.1161/res.121.suppl_1.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
It is known that an endogenous blood coagulation factor Xa (FXa) plays a critical role in facilitating atherosclerosis by activating protease-activated receptor-2 (PAR-2). However, the precise mechanism how FXa-mediated PAR-2 activation promotes atherogenesis remains to be elucidated.
Purpose:
The aim of this study is to explore how FXa promotes atherosclerosis through PAR-2-associated signaling pathway.
Methods & Results:
Administration of direct FXa inhibitor rivaroxaban (Riv; 120 mg/kg/day) to the mice significantly suppressed the plasma FXa activity compared with untreated mice. Administration of Riv to ApoE knockout mice fed with high fat diet (ApoE-KO-HFD) significantly reduced atherosclerotic area in the aorta compared with those in the untreated ApoE-KO-HFD. The plaque size of ApoE-KO mice crossed with PAR-2 knockout mice fed with HFD was similar to those of Riv-treated ApoE-KO-HFD. Ultrastructural examinations of atherosclerotic lesions revealed that the number of autophagosomes in the plaque-resident macrophages of Riv-treated ApoE-KO-HFD was significantly smaller than those of the untreated ApoE-KO-HFD. Immunostaining of NLRP3 revealed that Riv attenuated the inflammasome formation in the atherosclerotic lesion in ApoE-KO-HFD.
In vitro
experiments demonstrated that treatment of 7-ketocholesterol (7KC) markedly enhanced autophagy activity in the murine macrophages. The addition of FXa significantly promoted mTOR (Ser
2448
) phosphorylation and blocked autophagy activity induced by 7KC, which was reversed in the presence of Riv (1 μM). Furthermore, immunoblot analyses demonstrated that FXa administration significantly accelerated inflammasome formation induced by 7KC, which was blocked in the presence of Riv. On the other hand, treatment with FXa failed to inhibit 7KC-induced autophagy and inflammasome activation in PAR-2-KO mice-derived macrophages.
Conclusion:
These results suggest that FXa worsens atherogenesis through PAR-2-mediated pathway by inhibiting macrophage autophagy which, in turn, promoting inflammasome activation.
Collapse
|
43
|
Minatoya M, Itoh S, Araki A, Tamura N, Yamazaki K, Nishihara S, Miyashita C, Kishi R. Associated factors of behavioural problems in children at preschool age: the Hokkaido study on environment and children's health. Child Care Health Dev 2017; 43:385-392. [PMID: 27868227 DOI: 10.1111/cch.12424] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 09/27/2016] [Accepted: 10/09/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Finding associated factors with childhood behavioural problems as early as preschool age is important. Studies have revealed several factors including socioeconomic factors, which may vary among different cultural background and population. However, investigation in general Japanese population of preschool age has not been well demonstrated. Thus, the objective of this study was to examine associated factors of childhood behavioural problems using Strengths and Difficulties Questionnaire (SDQ) in a prospective birth cohort study. METHODS Total 3813 SDQ were distributed between October 2014 and December 2015 to the subpopulation of prospective birth cohort study, the Hokkaido Study on Environment and Children's Health. The subpopulation consisted of participants who had reached age 5 and were born between April 2008 and December 2010. Baseline questionnaire filled at recruitment and birth record were used to obtain participant information. Children with total difficulties score ≧ 13 were defined as likelihood of behavioural problems. A total of 2553 children with valid answers were included into the analysis. The response rate was 67.1%. RESULTS Number of children with likelihood of behavioural problems was 521 (20.4%). Boys showed more problematic scores than girls. Multivariate analysis found that maternal pre-pregnancy BMI ≧ 30 kg/m2 , primipara, maternal education lower than high school, family income during pregnancy < 3 million yen/year and boy gender were the factors associated with increased odds ratio of likelihood of child behavioural problems. CONCLUSIONS This study found that prenatal socioeconomic factors were associated with likelihood of child behavioural problems at preschool age in Japan.
Collapse
Affiliation(s)
- M Minatoya
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - S Itoh
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - A Araki
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - N Tamura
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - K Yamazaki
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - S Nishihara
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - C Miyashita
- Center for Environmental and Health Sciences, Sapporo, Japan
| | - R Kishi
- Center for Environmental and Health Sciences, Sapporo, Japan
| |
Collapse
|
44
|
Komori A, Morisaki T, Mutoh T, Sakakibara S, Takeiri Y, Kumazawa R, Kubo S, Ida K, Morita S, Narihara K, Shimozuma T, Tanaka K, Watanabe KY, Yamada H, Yoshinuma M, Akiyama T, Ashikawa N, Emoto M, Funaba H, Goto M, Ido T, Ikeda K, Inagaki S, Isobe M, Igami H, Itoh K, Kaneko O, Kawahata K, Kobuchi T, Masuzaki S, Matsuoka K, Minami T, Miyazawa J, Muto S, Nagayama Y, Nakamura Y, Nakanishi H, Narushima Y, Nishimura K, Nishiura M, Nishizawa A, Noda N, Ohdachi S, Oka Y, Osakabe M, Ohyabu N, Ozaki T, Peterson BJ, Sagara A, Saito K, Sakamoto R, Sato K, Sato M, Seki T, Shoji M, Sudo S, Tamura N, Toi K, Tokuzawa T, Tsumori K, Uda T, Watari T, Yamada I, Yokoyama M, Yoshimura Y, Motojima O, Beidler CD, Fujita T, Isayama A, Sakamoto Y, Takenaga H, Goncharov P, Ishii K, Sakamoto M, Murakami S, Notake T, Takeuchi N, Okajima S, Sasao M. Overview of Progress in LHD Experiments. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1229] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Komori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Igami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Minami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Muto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Sato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Uda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - C. D. Beidler
- Max-Planck Institut fuer Plasmaphysik, Greifswald D-17491, Germany
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - P. Goncharov
- Graduate University for Advanced Studies, School of Mathematical and Physical Science Department of Fusion Science, Hayama 240-0193, Japan
| | - K. Ishii
- Kyushu University, Research Institute for Applied Mechanics Kasuga 816-8580, Japan
| | - M. Sakamoto
- Kyushu University, Research Institute for Applied Mechanics Kasuga 816-8580, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - T. Notake
- Nagoya University, Department of Energy Engineering and Science Nagoya 464-8603, Japan
| | - N. Takeuchi
- Nagoya University, Department of Energy Engineering and Science Nagoya 464-8603, Japan
| | - S. Okajima
- Chubu University, Kasugai, Aichi 487-8501, Japan
| | - M. Sasao
- Tohoku University, Graduate School of Engineering, Sendai 980-8579, Japan
| | | |
Collapse
|
45
|
Yamada H, Ida K, Murakami S, Watanabe KY, Ascasibar E, Brakel R, Dinklage A, Harris JH, Okamura S, Sano F, Stroth U, Inagaki S, Tanaka K, Goto M, Nishimura K, Narihara K, Morita S, Sakakibara S, Peterson BJ, Sakamoto R, Miyazawa J, Morisaki T, Osakabe M, Toi K, Tamura N, Ikeda K, Yamazaki K, Kawahata K, Kaneko O, Ohyabu N, Komori A, Motojima O. Configuration Effect on Energy Confinement and Local Transport in LHD and Contribution to the International Stellarator Database. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a543] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | | | - R. Brakel
- Max-Planck-Institut für Plasmaphysik, D-17941 Greifswald, Germany
| | - A. Dinklage
- Max-Planck-Institut für Plasmaphysik, D-17941 Greifswald, Germany
| | - J. H. Harris
- Australian National University, Plasma Research Laboratory, Canberra, ACT 0200, Australia
| | - S. Okamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - F. Sano
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - U. Stroth
- University of Kiel, Institute of Experimental and Applied Physics, 24098 Kiel, Germany
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | | | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | | |
Collapse
|
46
|
Shimozuma T, Yokoyama M, Ida K, Takeiri Y, Kubo S, Murakami S, Wakasa A, Idei H, Yoshimura Y, Notake T, Inagaki S, Tamura N, Toi K, Ohyabu N, Osakabe M, Ikeda K, Tsumori K, Oka Y, Nagaoka K, Kaneko O, Yamada I, Narihara K, Nagayam Y, Muto S, Tanaka K, Tokuzawa T, Morita S, Goto M, Yoshinuma M, Funaba H, Morisaki T, Watanabe KY, Miyazawa J, Mutoh T, Watari T, Ohkubo K. Improvement of Plasma Core Confinement Via Electron-Root Realization by Strongly Focused ECRH in LHD: Core Electron-Root Confinement. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10791] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Shimozuma
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - A. Wakasa
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - H. Idei
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Notake
- RIKEN, Tera-Photonics Laboratory, Aoba Sendai-City, Miyagi 980-0845, Japan
| | - S. Inagaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - N. Tamura
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Nagayam
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Muto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
47
|
Yoshinuma M, Ida K, Yokoyama M, Osakabe M, Nagaoka K, Morita S, Goto M, Tamura N, Suzuki C, Yoshimura S, Funaba H, Takeiri Y, Ikeda K, Tsumori K, Kaneko O. Spontaneous Toroidal Flow and Impurity Hole in the High Ion Temperature Plasma on LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10797] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Yoshinuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - C. Suzuki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | | |
Collapse
|
48
|
Goncharov PR, Ozaki T, Sudo S, Tamura N, Kalinina DV, Veshchev EA, Sergeev VY. Active Neutral Particle Diagnostics on LHD by Locally Enhanced Charge Exchange on an Impurity Pellet Ablation Cloud. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1239] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- P. R. Goncharov
- National Institute for Fusion Science Particle Beam Heated Plasma Research Division, 322-6 Oroshi, Toki, Gifu 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science Particle Beam Heated Plasma Research Division, 322-6 Oroshi, Toki, Gifu 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science Particle Beam Heated Plasma Research Division, 322-6 Oroshi, Toki, Gifu 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science Particle Beam Heated Plasma Research Division, 322-6 Oroshi, Toki, Gifu 509-5292, Japan
| | - D. V. Kalinina
- National Institute for Fusion Science Particle Beam Heated Plasma Research Division, 322-6 Oroshi, Toki, Gifu 509-5292, Japan
| | - E. A. Veshchev
- Graduate University for Advanced Studies Hayama, Kanagawa 240-0193, Japan
| | - V. Yu. Sergeev
- St. Petersburg Polytechnical University St. Petersburg 195251, Russia
| | | | | |
Collapse
|
49
|
Tamura N, Inagaki S, Tokuzawa T, Michael C, Tanaka K, Ida K, Shimozuma T, Kubo S, Itoh K, Nagayama Y, Kawahata K, Sudo S, Komori A. Experimental Study on Nonlocality of Heat Transport in LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10799] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - S. Inagaki
- Research Institute for Applied Mechanics, Kyushu University, 6-1 Kasuga-kouen Kasuga Fukuoka 816-8580, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - C. Michael
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | | |
Collapse
|
50
|
Miyazawa J, Masuzaki S, Sakamoto R, Peterson BJ, Tamura N, Goto M, Kobayashi M, Shoji M, Akiyama T, Yamada H. Density Limits for the Core and Edge Plasmas Related to the Local Temperatures in LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10807] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Miyazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | | |
Collapse
|